Pacer Advisors Inc. Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)


Share on StockTwits

Pacer Advisors Inc. trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 46.2% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 550 shares of the biopharmaceutical company’s stock after selling 472 shares during the period. Pacer Advisors Inc.’s holdings in Alnylam Pharmaceuticals were worth $78,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of ALNY. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth about $38,000. Ellevest Inc. boosted its stake in Alnylam Pharmaceuticals by 24.1% during the fourth quarter. Ellevest Inc. now owns 695 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 135 shares during the period. Signaturefd LLC boosted its stake in shares of Alnylam Pharmaceuticals by 98.5% in the fourth quarter. Signaturefd LLC now owns 953 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 473 shares during the period. MUFG Americas Holdings Corp lifted its stake in Alnylam Pharmaceuticals by 34.5% in the fourth quarter. MUFG Americas Holdings Corp now owns 974 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 250 shares during the last quarter. Finally, Winslow Evans & Crocker Inc. raised its holdings in Alnylam Pharmaceuticals by 16.8% during the fourth quarter. Winslow Evans & Crocker Inc. now owns 1,285 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 185 shares in the last quarter. Institutional investors and hedge funds own 92.35% of the company’s stock.

Shares of NASDAQ:ALNY opened at $136.03 on Wednesday. The firm has a market cap of $15.96 billion, a P/E ratio of -17.37 and a beta of 1.47. Alnylam Pharmaceuticals, Inc. has a 12-month low of $119.29 and a 12-month high of $178.41. The business has a fifty day simple moving average of $140.50 and a 200 day simple moving average of $141.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, February 10th. The biopharmaceutical company reported ($2.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.76) by ($0.33). Alnylam Pharmaceuticals had a negative return on equity of 65.96% and a negative net margin of 222.19%. The firm had revenue of $163.56 million for the quarter, compared to analysts’ expectations of $142.49 million. During the same quarter in the prior year, the company posted ($2.47) earnings per share. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -7.32 earnings per share for the current fiscal year.

ALNY has been the topic of a number of recent research reports. Citigroup cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their target price for the company from $170.00 to $175.00 in a report on Friday, February 12th. Morgan Stanley upped their price objective on shares of Alnylam Pharmaceuticals from $203.00 to $206.00 and gave the company an “overweight” rating in a research note on Friday, February 12th. HC Wainwright increased their target price on shares of Alnylam Pharmaceuticals from $225.00 to $235.00 and gave the stock a “buy” rating in a research report on Friday, February 12th. Barclays increased their target price on Alnylam Pharmaceuticals from $162.00 to $196.00 and gave the company an “overweight” rating in a research note on Friday, February 12th. Finally, Royal Bank of Canada reissued a “hold” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, February 14th. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Alnylam Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $166.41.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Read More: How is an ETF different from a mutual fund?

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.